ScoreWhy is Parmax Pharma Ltd ?
1
With HIgh Debt (Debt-Equity Ratio at 5.86 times)- the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 6.91% and Operating profit at 0% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.66
2
Risky - Negative Operating Profits
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 27.02%, its profits have risen by 50.4%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Drugs)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Parmax Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Parmax Pharma
27.74%
0.38
70.41%
SENSEX
0.45%
0.02
14.48%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
6.91%
EBIT Growth (5y)
-194.14%
EBIT to Interest (avg)
0.66
Debt to EBITDA (avg)
1.22
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.75
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
-7.29%
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
33
Price to Book Value
16.72
EV to EBIT
-14.20
EV to EBITDA
22.58
EV to Capital Employed
3.79
EV to Sales
0.82
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-84.90%
ROE (Latest)
-205.00%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend9What is working for the Company
NET SALES(HY)
At Rs 15.56 cr has Grown at 188.15%
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Parmax Pharma
Net Sales - Half Yearly
At Rs 15.56 cr has Grown at 188.15%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (Rs Cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
